Slide 1: Business Update Conference Call
1 Developing clinical - stage products in neurology, psychiatry and orphan indications BUSINESS UPDATE CONFERENCE CALL May 27, 2015 OTCQB: AMBS
Slide 2: Forward-Looking Statements
This presentation contains “ forward - looking statements ” within the meaning of the “ safe - harbor ” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Comp
Slide 3: Agenda
3 Agenda • INTRODUCTION • Q1 FINANCIAL REVIEW • CORPORATE OUTLOOK • THERAPEUTICS DIVISION REVIEW • DIAGNOSTICS DIVISION REVIEW • 2015 EXPECTED MILESTONES • Q&A
Slide 4: Rich Pipeline Expected to Yield Transformational Opportunities
Rich Pipeline Expected to Yield Transformational Opportunities 4 Asset Pre - Clinical Phase 1 Phase 2 Phase 3 Value Driving Milestone Potential strategic transaction in 2015 Eltoprazine: PD - LID Phase 2b program clinical data in 2016 ESS*: 50+% TBSA Severe Burns Phase 2 clinical data in 2016 MANF:
Slide 5: Poised for Next Phase of Growth
5 Poised for Next Phase of Growth Therapeutics Division • Eltoprazine on track to commence Phase 2b study before end of 2Q 2015 • Lonza transaction expected to be completed by August 2015, with Phase 2 study of ESS to commence in 3Q 2015 after acquisition* • MANF orphan ocular diseases strategy esta
Slide 6: Financial Review
Financial Review 6
Slide 7: Corporate Outlook
Corporate Outlook 7
Slide 8: Path to Up-listing
Path to Up - listing 8 Access to Lincoln Park Capital Facility Series E primarily for ESS and MSPrecise transactions Series G ‘bridge’ financing to NASDAQ NASDAQ IPO(s) Strategic Transaction to fuel pipeline
Slide 9: NASDAQ IPO: Why Now?
NASDAQ IPO: Why Now? • Core fundamentals have never been stronger and improving – In spite of achieving recent important milestones, share price has declined – Stock unable to hold gains due to short - term trading interests – Greater access to long - term institutional investors and research analys
Slide 10: Reverse Split Rationale: NASDAQ Listing
Reverse Split Rationale: NASDAQ Listing • Reverse split does not change AMBS stockholder value or market cap • Increased share price will make AMBS more attractive to larger investors while still on OTC preparing for national exchange listing • Post - split share structure meets NASDAQ Capital Marke
Slide 11: Therapeutics Division Review
Therapeutics Division Review 11
Slide 12: Eltoprazine: Recent Milestone Achievements
Eltoprazine: Recent Milestone Achievements x Published Phase 2a clinical study results in BRAIN for the treatment of PD - LID x Opened an IND with the neurology division of the FDA to advance Eltoprazine into Phase 2b clinical studies x Completed Investigator Meetings in US and EU x Entered into a c
Slide 13: Eltoprazine Phase 2b study on Track to Commence 2Q 2015
Eltoprazine Phase 2b study on Track to Commence 2Q 2015 13 • Double - blind placebo - controlled, dose range finding study • 60 patient, four way crossover (each patient receives all dosing regiments) • Twice daily dosing, 3 weeks per dosing regimen (12 weeks total) • Expert PD centers in US and EU
Slide 14: MANF: Recent Milestone Achievements
MANF: Recent Milestone Achievements x Announced the successful delivery and distribution of MANF in a preclinical model to brain areas involved in Parkinson's disease , further solidifying the rationale for its preclinical development as a potential disease - modifying treatment for PD x Entered int
Slide 15: MANF has Blue-Sky Potential
MANF has “Blue - Sky” Potential • Potential paradigm shift in cell protection and restoration – Collaboration w/ Buck Institute yielding tremendous results – 75+ peer - reviewed publications • $Multi - billion opportunity: Breakthrough science • Lead programs in orphan ocular indications – Retinitis
Slide 16: Cutanogen Acquisition Could Add Significant Value
Cutanogen Acquisition Could Add Significant Value* • Autologous, skin graft replacement for 50+% TBSA severe burns • Biologics/drug regulatory pathway in office of combination products • Orphan Drug Designation received in 2012 • Active IND as of May 2014 • Partially funded by US Gov’t grant: AFIRM
Slide 17: Diagnostics
Amarantus DIAGNOSTICS
Slide 18: Diagnostic Candidates
Diagnostic Candidates Clinical Validation Analytical Performance Commercialization LymPro Test ® MSPrecise ® Georgetown Assays* Alzheimer's Disease Multiple Sclerosis Alzheimer’s Disease Exploring Strategic Options for Monetization Preparing for “Exit Strategy” to Unlock Value 18 *Upon exercise of e
Slide 19: Diagnostics Division: Pipeline Achievements
Diagnostics Division: Pipeline Achievements LymPro Test ® • Initiated business development activity with the pharmaceutical industry for Investigational Use Only (IUO) LymPro Test biomarker services • Established the first Investigational Use Only (IUO) Alzheimer's biomarker services collaboration w
Slide 20: Business Development Update
• Currently available as IUO for clinical trials • Completed multivariate analysis to support CLIA pathway • Two late - breaking abstract submitted to expected to be presented at AAIC • Business development initiative gaining traction Business Development Update 20 Commence due diligence Initial Con
Slide 21: Exit Strategy Accelerated as a Priority
21 “Exit” Strategy Accelerated as a Priority • In process of engaging investment bank(s) to evaluating strategic options for the diagnostics business unit • Potential options under consideration – Potential sale of the division for cash (and maintain a royalty) – IPO or RTO – License the technologie
Slide 22: Expected Milestones
Expected Milestones • Initiate Phase 2 b clinical study of Eltoprazine in PD - LID in 2 Q 2015 • Complete enrollment of Phase 2 b clinical study of Eltoprazine in PD - LID • Complete acquisition of Cutanogen – Initiate Phase 2 study of ESS expected in 3 Q 2015 • MANF progression towards first - in -
Slide 23: Developing clinical-stage products in neurology, psychiatry and orphan indications
23 Developing clinical - stage products in neurology, psychiatry and orphan indications OTCQB: AMBS